IRIX
IRIDEX Corporation
There isn't enough reported data to score IRIX yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
IRIX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IRIX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
IRIX PE Valuation
IRIX has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
IRIX Forward outlook
There aren't enough analyst estimates for IRIX to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
IRIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.20 | +$0.13 |
| Q1 2026 | -$0.19 | +$0.24 |
| Q4 2025 | -$0.26 | +$0.28 |
| Q3 2025 | -$0.30 | +$0.37 |
| Q2 2025 | -$0.33 | +$0.33 |
| Q1 2025 | -$0.43 | +$0.24 |
| Q4 2024 | -$0.54 | +$0.05 |
| Q3 2024 | -$0.67 | -$0.19 |
IRIX is still losing money, but far less than before: $0.20 per share over the past year, against $0.73 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over IRIX on earnings quality, reporting a profit while its opponent remains loss making.
IRIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $12.6M | -7.4% |
| Q1 2026 | $11.8M | -0.8% |
| Q4 2025 | $14.7M | +16% |
| Q3 2025 | $12.5M | +7.8% |
| Q2 2025 | $13.6M | +7.4% |
| Q1 2025 | $11.9M | +1.1% |
| Q4 2024 | $12.7M | +1.9% |
| Q3 2024 | $11.6M | -9.9% |
IRIX's revenue fell from its 2022 peak and has held roughly level since: $13M last quarter, down 7.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -8.2% | -1.3 points |
| Q1 2026 | -2.8% | -1 points |
| Q4 2025 | -0.1% | +3.9 points |
| Q3 2025 | -11% | +4.8 points |
| Q2 2025 | -6.9% | +14 points |
| Q1 2025 | -1.7% | +26 points |
| Q4 2024 | -4% | +21 points |
| Q3 2024 | -16% | -3 points |
IRIX's operating margin was −8.2% last quarter, down 1.3 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over IRIX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over IRIX on profitability, with a higher operating margin.
IRIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $124K | +$534K |
| Q1 2026 | -$1.4M | -$276K |
| Q4 2025 | $483K | +$1.7M |
| Q3 2025 | -$1.2M | +$1.9M |
| Q2 2025 | -$410K | +$916K |
| Q1 2025 | -$1.2M | +$491K |
| Q4 2024 | -$1.2M | -$300K |
| Q3 2024 | -$3.1M | -$1.2M |
IRIX has burned cash in almost every quarter: −$2M over the past year, against −$6M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over IRIX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IRIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +107K shares |
| 1 year | +3.7% | +625K shares |
| 3 years | +8.6% | +1.4M shares |
| 5 years | +6.8% | +1.1M shares |
| Available history | +27% | +3.6M shares |
IRIX has 17M diluted shares, up 3.7% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over IRIX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
IRIX Net Leverage
IRIX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
IRIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.1 | Neutral |
| Stochastic | 20.8 | Neutral |
IRIX's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
IRIX PE vs Healthcare Sector
IRIX has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IRIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 1.4% below |
| 20 week MA | $0.79 | 10% below |
| 50 week MA | $1.02 | 30% below |
| 100 week MA | $1.11 | 36% below |
| 200 week MA | $1.68 | 58% below |
IRIX is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over IRIX on trend strength, trading above more of its moving averages.
IRIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.35 | $1.94 | -17% |
| 2021 | $1.94 | $6.22 | +221% |
| 2022 | $6.22 | $2.11 | -66% |
| 2023 | $2.11 | $2.81 | +33% |
| 2024 | $2.81 | $1.67 | -41% |
| 2025 | $1.67 | $1.23 | -26% |
| 2026 YTD | $1.23 | $0.71 | -42% |
IRIX's yearly returns have swung widely, from +221% in 2021 to −66% in 2022. It's down 42% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over IRIX on returns for 2026, with the stronger performance.